| Name | Title | Contact Details |
|---|
MSC Group is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advanced Medical Reviews (AMR), one of the country`s top medical peer review organizations, delivers services to a diverse group of healthcare and legal organizations, including: health plans, managed care groups, workers` compensation and disability clients, TPA, IPA, Medical Groups, MSO, PPO, HMO, Medicaid and Medicare teams, hospitals and government entities. Our dedicated medical management team and staff provide a variety of review services: independent medical case review, workers` compensation, medical evaluation, utilization review, and audits. Utilizing innovative healthcare technologies, AMR delivers a single source solution for our clients` managed healthcare administration needs.
Orlando Senior Health Network is a network of companies that provides a broad range of residential living options, home care and rehabilitation services, plus pharmaceutical and medical equipment offerings, designed to improve the quality of life for s...
Xincon Home Healthcare Services is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.